The administration has moved certain marijuana products from Schedule I to Schedule III, opening research and tax changes without legalizing recreational cannabis
The United States has taken a notable step in federal drug policy by reclassifying certain marijuana products that are either covered by the Food and Drug Administration (FDA) or sold through state medical programs. The action, announced by Acting Attorney General Todd Blanche, shifts those products out of Schedule I—the category for drugs deemed to have a “high potential for abuse” and no accepted medical use—into Schedule III, a tier reserved for substances judged to carry “a moderate to low potential for physical and psychological dependence”.
The Department of Justice emphasized that this administrative change does not legalize recreational or medical marijuana under federal law.
The reclassification is targeted: it applies to state-licensed medical cannabis and to marijuana-derived medicines that have FDA oversight. Products that remain outside state-licensed programs continue to be treated as Schedule I substances.
Officials say the move is intended to facilitate research into safety and effectiveness and to remove some federal obstacles for state medical programs, but it stops short of fully removing cannabis from the federal controlled substances framework.
What the change means in practice
At its core, moving eligible cannabis products into Schedule III changes how the federal government regulates them. Practically, the decision creates an expedited path for state-licensed producers and distributors to register with the Drug Enforcement Administration (DEA), clarifies that researchers may obtain state-authorized material without fear of federal penalties, and alters tax treatment by allowing certain businesses to claim typical business expense deductions on federal returns. Supporters say these adjustments will reduce compliance burdens for the industry and improve medical oversight by making clinical study and data collection easier.
Limits and legal questions
The Department of Justice was careful to note the boundaries of the action. Because the order addresses only products that are FDA-covered or state-licensed, it leaves a wide range of cannabis products in their prior status. Once the rule is published in the Federal Register it will be subject to a 30-day window and can face legal challenges that may delay or block implementation. Officials have also announced a series of hearings starting in June to consider broader reclassification of cannabis, signalling that further changes could follow but are not guaranteed.
Political and public reaction
Advocates of looser federal restrictions hailed the change as a long-overdue correction, noting the historical inconsistency of treating marijuana alongside drugs like heroin. They argue that moving certain cannabis products to Schedule III creates space for policy discussions that focus on regulation and public health rather than blanket criminalization. Critics, however, see risks: some argue the decision amounts to a tax and regulatory windfall for larger commercial operators while potentially sending mixed messages about harm. Opponents have also warned about the need for robust research into more potent products now common in regulated markets.
Polling, markets and state context
Federal policy now operates against a backdrop of widespread state-level change. About 40 states have legalized marijuana in some form; roughly two dozen states plus Washington, D.C. permit adult recreational use, while others allow medical access or low-THC products. A 2026 Pew Research Center poll found that 57 percent of adults supported legalization for both medical and recreational use, and the CDC has reported that one in five Americans used marijuana in the past year. Analysts also see a growing industry: market researchers such as BDSA have forecast rising legal sales through 2026.
How this move fits into the broader timeline
The action follows administrative momentum that began under previous administrations: a review initiated during the Biden presidency produced agency recommendations but was not finalized by the time he left office in January 2026. President Donald Trump directed his administration to move forward with reclassification efforts late in his term, and this order implements a targeted, immediate change while setting the stage for possible broader revisions. The Department of Justice says the change will facilitate more robust clinical study and improve patient care, even as advocates continue to press for full federal descheduling.
Ultimately, this reclassification represents a middle ground between prohibition and full legalization. It alters federal handling of state-licensed medical cannabis and FDA-covered products—adjusting research, tax treatment, and regulatory routes—without overturning the federal ban on recreational use. Watch for the June hearings and likely legal challenges that will determine how quickly and completely these reforms affect the cannabis landscape.
